A critical review of the full economic evaluations of pharmacological treatments for glaucoma
Authors:
- Paola De CompadriPCPaola De Compadri
- Gianni VirgiliGVGianni Virgili
- Alessandro NobiliANAlessandro Nobili
- Livio GarattiniLGLivio Garattini
- 1 January 2008
- journal article
- review article
- Published by Informa Healthcare in Journal of Medical Economics
- Vol. 11 (4) , 719-741
Abstract
(2008). A critical review of the full economic evaluations of pharmacological treatments for glaucoma. Journal of Medical Economics: Vol. 11, No. 4, pp. 719-741. doi: 10.3111/13696990802399548Keywords
This publication has 42 references indexed in Scilit:
- The Economic Implications of GlaucomaPharmacoEconomics, 2007
- The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countriesCurrent Medical Research and Opinion, 2006
- BimatoprostPharmacoEconomics, 2006
- Cost Considerations in the Medical Management of Glaucoma in the USPharmacoEconomics, 2006
- Prostaglandin Analogues for the Treatment of Glaucoma and Ocular HypertensionPharmacoEconomics, 2006
- The Diffusion of Health Economics Knowledge in EuropePharmacoEconomics, 2005
- Assessing the cost-effectiveness of switching from a β-blocker to latanoprost in the treatment of ocular hypertensionExpert Opinion on Pharmacotherapy, 2003
- Cost and effectiveness of brinzolamide versus dorzolamide in current practice: an analysis based on the UK-GPRD databaseJournal of Medical Economics, 2003
- Cost-Minimisation Study of Dorzolamide versus Brinzolamide in the Treatment of Ocular Hypertension and Primary Open-Angle GlaucomaPharmacoEconomics, 2003
- Economic Evaluation of PharmaceuticalsPharmacoEconomics, 1992